Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient

Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient

BackgroundWith the introduction of eculizumab, a C5-inhibitor, morbidity and mortality improved significantly for patients with atypical hemolytic uremic syndrome (aHUS). In view of the high costs, actual needs of the drug, and increasing evidence in literature, aHUS patients can be treated accordin...

Full description

Bibliographic Details
Main Authors: Romy N. Bouwmeester, Mendy Ter Avest, Kioa L. Wijnsma, Caroline Duineveld, Rob ter Heine, Elena B. Volokhina, Lambertus P. W. J. Van Den Heuvel, Jack F. M. Wetzels, Nicole C. A. J. van de Kar
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Immunology
Subjects:
atypical hemolytic uremic syndrome
aHUS
eculizumab
therapeutic drug monitoring
pharmacokinetic
proteinuria
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2020.612706/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2020.612706/full

Similar Items